MedPath

Comparison of the Effects of Remifentanil and Dexmedetomidine Administered Under General Anesthesia in Rhinoplasty

Phase 4
Completed
Conditions
Dexmedetomidine
Remifentanil
Rhinoplasty
Interventions
Registration Number
NCT05572723
Lead Sponsor
Baskent University
Brief Summary

The investigators compared the effects of remifentanil and dexmedetomidine administered under general anesthesia on hemodynamics, postoperative pain, recovery, postoperative nausea, vomiting, shivering, patient's and surgeon's satisfaction in patients undergoing elective rhinoplasty. A single-center, prospective, blinded, randomized controlled trial. After the approval of the hospital ethics committee (KA22/12), fifty volunteers aged 18-65 years who underwent rhinoplasty under elective conditions accepted the study in the American Society of Anesthesiologists (ASA) I-III class. The patients were randomly divided into the remifentanil group (group R) and the dexmedetomidine group (group D). Group R (n=25) was initially to receive remifentanil 0.01-0.2 g/kg/min without intraoperative loading. Group D (n=25) dexmedetomidine, was initiated with a bolus of 1 mg/kg and received 0.2-0.7 g/kg per hour as an infusion during surgery.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
50
Inclusion Criteria

Patients who will have rhinoplasty surgery American Society of Anesthesiologists (ASA) I- II class

Read More
Exclusion Criteria

Patients with end-stage liver or kidney disease Uncontrolled hypertension Any type of atrioventricular block, pacemaker Heart failure Diabetes mellitus Chronic obstructive or interstitial lung disease, severe asthma Neurological or psychiatric disease, substance abuse Pregnant or lactating women

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
FACTORIAL
Arm && Interventions
GroupInterventionDescription
Group RemifentanilRemifentanil 2 MGRemifentanil group was initially to receive remifentanil (group R), 0.01-0.2 g/kg/min without intraoperative loading.
Group DexmedetomidinedexmedetomidineDexmedetomidine group, dexmedetomidine (group D) was initiated with a bolus of 1 mg/kg and received 0.2-0.7 g/kg per hour as an infusion during surgery.
Primary Outcome Measures
NameTimeMethod
Mean arterial pressureDuring surgery

The investigators compare the stability of mean arterial pressure.

Postoperative painUp to 30 minutes after the patient wakes up.

The investigators compare the effect of remifentanil and dexmedetomidine on postoperative pain. The patients pain level was assessed using the numeric pain scale (Between 0-10, 0 = no pain, 10 = worst pain).

Patient Recovery TimePostoperative 1. hours

The investigators compare the effect of remifentanil and dexmedetomidine on patient recovery time. The recovery time of the patient will be evaluated by calculating the time between extubated and discharged from the postoperative care unit.

Secondary Outcome Measures
NameTimeMethod
Postoperative nausea and vomiting scorespostoperative first 6 hours and 24 hours

The investigators compare the effect of remifentanil and dexmedetomidine on nausea and vomiting. The presence of PONV was assessed using the Verbal Descriptor Scale (Between 0-3, 0=no nausea, 1=mild, 2=moderate, 3=severe).

Patient satisfactionPostoperative 6. hours

The investigators will question patients' degree of postoperative satisfaction. The patient satisfaction scale was used to assess the surgical outcome (Between 1 - 5, 1 = very poor, 5 = very good).

Surgeon satisfactionPostoperative 0. hours

The investigators will question surgeons' degree of satisfaction. The surgical satisfaction scale was used to assess the surgical outcome (Between 1 - 5, 1 = very poor, 5 = excellent).

Trial Locations

Locations (1)

Baskent University Medical School

🇹🇷

Ankara, Turkey

© Copyright 2025. All Rights Reserved by MedPath